Effect of cyclosporin on distribution of methotrexate into the brain of rats

Journal of Veterinary Medical Science

Volumn 77, Issue 9, 2015, Pages 1171-1173

  Ogushi, Naofumi ^a,b   Sasaki, Kazuaki ^a   Shimoda, Minoru ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^b Ogushi Animal Hospital   (Japan)

Author keywords

Cyclosporine A; Intrathecal administration; Methotrexate; P glycoprotein

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD BRAIN BARRIER; BRAIN CHEMISTRY; DRUG EFFECTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRASPINAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; INJECTIONS, INTRAVENOUS; INJECTIONS, SPINAL; MALE; METHOTREXATE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84940946062     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.14-0671     Document Type: Note

References (13)

1. Abelson, H. T., Kufe, D. W., Skarin, A. T., Major, P., Ensminger, W., Beardsley, G. P. and Canellos, G. P. 1981. Treatment of central nervous system tumors with methotrexate. Cancer Treat. Rep. 65 Suppl 1: 137–140. [Medline]
2. Arceci, R. J. 1993. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81: 2215–2222. [Medline]
3. Assaraf, Y. G., Rothem, L., Hooijberg, J. H., Stark, M., Ifergan, I., Kathmann, I., Dijkmans, B. A., Peters, G. J. and Jansen, G. 2003. Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J. Biol. Chem. 278: 6680–6686. [Medline] [CrossRef]
4. Cordon-Cardo, C., O’Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R. and Bertino, J. R. 1989. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U.S.A. 86: 695–698. [Medline] [CrossRef]
5. Miller, D. S. 2010. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol. Sci. 31: 246–254. [Medline] [CrossRef]
6. de Graaf, D., Sharma, R. C., Mechetner, E. B., Schimke, R. T. and Roninson, I. B. 1996. P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc. Natl. Acad. Sci. U.S.A. 93: 1238–1242. [Medline] [CrossRef]
7. de Lange, E. C. M. 2004. Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv. Drug Deliv. Rev. 56: 1793–1809. [Medline] [CrossRef]
8. Gottesman, M. M. 1993. How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 53: 747–754. [Medline]
9. Laquintana, V., Trapani, A., Denora, N., Wang, F., Gallo, J. M. and Trapani, G. 2009. New strategies to deliver anticancer drugs to brain tumors. Expert Opin. Drug Deliv. 6: 1017–1032. [Medline] [CrossRef]
10. Ling, V. 1992. Charles F. Kettering Prize. P-glycoprotein and resistance to anticancer drugs. Cancer 69: 2603–2609. [Medline] [CrossRef]
11. Schinkel, A. H., Smit, J. J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., Berns, A. J. M. and Borst, P. 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491–502. [Medline] [CrossRef]
12. Sikic, B. I., Fisher, G. A., Lum, B. L., Halsey, J., Beketic-Oreskovic, L. and Chen, G. 1997. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother. Pharmacol. 40 Suppl: S13–S19. [Medline] [Cross-Ref]
13. Wolburg, H. and Paulus, W. 2010. Choroid plexus: biology and pathology. Acta Neuropathol. 119: 75–88. [Medline] [CrossRef]